Teva Pharmaceutical Industries Limited (TEVA)
NYSE: TEVA · Real-Time Price · USD
18.34
-0.02 (-0.11%)
At close: Sep 26, 2025, 4:00 PM EDT
18.49
+0.15 (0.82%)
After-hours: Sep 26, 2025, 7:58 PM EDT
Teva Pharmaceutical Stock Forecast
Stock Price Forecast
According to 7 professional analysts, the 12-month price target for Teva Pharmaceutical stock ranges from a low of $22 to a high of $30. The average analyst price target of $25.14 forecasts a 37.08% increase in the stock price over the next year.
Price Target: $25.14 (+37.08%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Teva Pharmaceutical stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 | Sep '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 3 | 4 | 5 | 5 | 5 | 4 |
| Buy | 2 | 3 | 3 | 3 | 3 | 3 |
| Hold | 1 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 7 | 8 | 8 | 8 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| UBS | UBS | Strong Buy Maintains $23 → $26 | Strong Buy | Maintains | $23 → $26 | +41.77% | Sep 24, 2025 |
| UBS | UBS | Strong Buy Maintains $24 → $23 | Strong Buy | Maintains | $24 → $23 | +25.41% | Jun 26, 2025 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $24 | Strong Buy | Initiates | $24 | +30.86% | Jun 6, 2025 |
| Truist Securities | Truist Securities | Strong Buy Initiates $25 | Strong Buy | Initiates | $25 | +36.31% | May 28, 2025 |
| JP Morgan | JP Morgan | Hold → Buy Upgrades $21 → $23 | Hold → Buy | Upgrades | $21 → $23 | +25.41% | May 12, 2025 |
Financial Forecast
Revenue This Year
17.22B
from 16.54B
Increased by 4.07%
Revenue Next Year
17.36B
from 17.22B
Increased by 0.81%
EPS This Year
2.63
from -1.45
EPS Next Year
2.74
from 2.63
Increased by 4.47%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 17.9B | 18.0B | |
| Avg | 17.2B | 17.4B | |
| Low | 16.5B | 16.5B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 7.9% | 4.5% | |
| Avg | 4.1% | 0.8% | |
| Low | -0.4% | -4.1% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | 2.75 | 2.99 | |
| Avg | 2.63 | 2.74 | |
| Low | 2.47 | 2.43 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 |
|---|---|---|---|
| High | - | 13.9% | |
| Avg | - | 4.5% | |
| Low | - | -7.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.